{"generic":"Drospirenone\/Ethinyl Estradiol","drugs":["Drospirenone\/Ethinyl Estradiol","Gianvi","Loryna","Ocella","Syeda","Yasmin","YAZ","Yaz 28","Zarah"],"mono":{"0":{"id":"926423-s-0","title":"Generic Names","mono":"Drospirenone\/Ethinyl Estradiol"},"1":{"id":"926423-s-1","title":"Dosing and Indications","sub":[{"id":"926423-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acne vulgaris (Moderate):<\/b> Yaz(R), 1 active (pink) tablet ORALLY every day for 24 consecutive days followed by 1 inert (white) tablet daily for 4 days per menstrual cycle<\/li><li><b>Acne vulgaris (Moderate):<\/b> Yaz(R), begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Acne vulgaris (Moderate):<\/b> Yaz(R), begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule<\/li><li><b>Contraception:<\/b> Yasmin(R), 1 yellow tablet ORALLY every day for 21 consecutive days followed by 1 white (inert) tablet daily for 7 days per menstrual cycle<\/li><li><b>Contraception:<\/b> Yaz(R), 1 pink tablet ORALLY every day for 24 consecutive days followed by 1 white (inert) tablet daily for 4 days per menstrual cycle<\/li><li><b>Contraception:<\/b> Yasmin(R) and Yaz(R), begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Contraception:<\/b> Yasmin(R) and Yaz(R), begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule<\/li><li><b>Contraception:<\/b> therapy may be initiated 4 weeks postpartum in nonlactating mothers<\/li><li><b>Premenstrual dysphoric disorder:<\/b> Yaz(R), 1 active (pink) tablet ORALLY every day for 24 consecutive days followed by 1 inert (white) tablet daily for 4 days per menstrual cycle<\/li><li><b>Premenstrual dysphoric disorder:<\/b> Yaz(R), begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Premenstrual dysphoric disorder:<\/b> Yaz(R), begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule<\/li><\/ul>"},{"id":"926423-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>use of this product before menarche is not indicated<\/li><li><b>Acne vulgaris (Moderate):<\/b> (14 years and older) after menarche, Yaz(R), 1 active (pink) tablet ORALLY every day for 24 consecutive days followed by 1 inert (white) tablet daily for 4 days per menstrual cycle <\/li><li><b>Acne vulgaris (Moderate):<\/b> (14 years and older) Yaz(R), begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Acne vulgaris (Moderate):<\/b> (14 years and older) Yaz(R), begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule<\/li><li><b>Contraception:<\/b> after menarche, Yasmin(R), 1 yellow tablet ORALLY every day for 21 consecutive days followed by 1 white (inert) tablet daily for 7 days per menstrual cycle<\/li><li><b>Contraception:<\/b> after menarche, Yaz(R), 1 pink tablet ORALLY every day for 24 consecutive days followed by 1 white (inert) tablet daily for 4 days per menstrual cycle<\/li><li><b>Contraception:<\/b> after menarche, Yasmin(R) and Yaz(R), begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Contraception:<\/b> after menarche, Yasmin(R) and Yaz(R), begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule<\/li><li><b>Contraception:<\/b> therapy may be initiated 4 weeks postpartum in nonlactating mothers<\/li><li><b>Premenstrual dysphoric disorder:<\/b> after menarche, Yaz(R), 1 active (pink) tablet ORALLY every day for 24 consecutive days followed by 1 inert (white) tablet daily for 4 days per menstrual cycle<\/li><li><b>Premenstrual dysphoric disorder:<\/b> Yaz(R), begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Premenstrual dysphoric disorder:<\/b> Yaz(R), begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule<\/li><\/ul>"},{"id":"926423-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> use contraindicated<\/li><li><b>hepatic impairment:<\/b> use contraindicated<\/li><\/ul>"},{"id":"926423-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acne vulgaris (Moderate)<\/li><li>Contraception<\/li><li>Premenstrual dysphoric disorder<\/li><\/ul>"}]},"2":{"id":"926423-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Women who are over 35 years of age and smoke should not use oral contraceptives.<br\/>"},"3":{"id":"926423-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926423-s-3-9","title":"Contraindications","mono":"<ul><li>adrenal insufficiency<\/li><li>breast cancer or other estrogen or progestin-sensitive cancer, current or past history<\/li><li>cerebrovascular disease<\/li><li>coronary artery disease<\/li><li>deep vein thrombosis or pulmonary embolism, current or past history<\/li><li>diabetes mellitus with vascular disease<\/li><li>headaches with focal neurological symptoms or migraine headaches with or without aura if over age 35 years<\/li><li>hepatic dysfunction<\/li><li>hepatic tumors, benign or malignant<\/li><li>hypercoagulopathies, inherited or acquired<\/li><li>hypertension, uncontrolled<\/li><li>pregnancy<\/li><li>renal insufficiency<\/li><li>smoking and over age 35 years<\/li><li>thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation)<\/li><li>uterine bleeding, undiagnosed, abnormal<\/li><\/ul>"},{"id":"926423-s-3-10","title":"Precautions","mono":"<ul><li>cigarette smoking, especially with high number of cigarettes smoked and increased age (over 35 years); increased risk of cardiovascular events including myocardial infarction<\/li><li>arterial or venous thrombotic events (VTE) may occur; possible increased risk of VTE with drospirenone-containing oral contraceptives combined with 0.03 mg of ethinyl estradiol over levonorgestrel or some other progestins; discontinue use if arterial or VTE occurs<\/li><li>cerebrovascular events (thrombotic and hemorrhagic stroke) may occur; increased risk over age 35 years and with hypertensive women who smoke or have underlying risk factors<\/li><li>chloasma may occur, especially with history of chloasma gravidarum<\/li><li>depression; exacerbation of depression may occur; discontinuation recommended for serious depression<\/li><li>diabetes (including prediabetic women); glucose tolerance may be impaired; monitoring recommended<\/li><li>dyslipidemia, uncontrolled; may exacerbate; consider alternative contraception<\/li><li>gallbladder disease may occur<\/li><li>headaches, new-onset and recurrent, persistent, or severe; evaluate and discontinue if necessary<\/li><li>hepatic adenoma or hepatocellular carcinoma may occur; increased risk associated with long-term use<\/li><li>hereditary angioedema; may induce or exacerbate symptoms<\/li><li>hyperkalemia may occur in high-risk patients; monitoring recommended when used concomitantly with daily maintenance medications known to increase serum potassium (ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDs)<\/li><li>hypertension may occur, especially in older women with extended duration of use; monitoring recommended; discontinue if necessary<\/li><li>hypertensive women who also smoke; increased risk of cerebrovascular events<\/li><li>hypertriglyceridemia, or family history of; increased risk of pancreatitis<\/li><li>jaundice may occur; discontinue use if this develops<\/li><li>migraine headaches that increase in frequency or severity; evaluate and discontinue if necessary<\/li><li>postpartum period; increased risk of thromboembolism, initiate no sooner than 4 weeks after delivery in women who are not breastfeeding<\/li><li>pregnancy-related cholestasis, past history, or cholestasis with prior hormonal contraceptive use; increased risk for recurrence<\/li><li>retinal vein thrombosis has occurred; discontinue use if unexplained ocular symptoms emerge (eg, loss of vision, diplopia, proptosis, papilledema, retinal vascular lesions)<\/li><li>surgery, major, or other surgeries with increased risk of thromboembolism; discontinue use 4 weeks before and through 2 weeks after procedure<\/li><li>vaginal bleeding abnormalities, including breakthrough bleeding, spotting, and amenorrhea, may occur; rule out malignancy, other pathology, or pregnancy<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"926423-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Drospirenone: X (FDA)<\/li><li>Ethinyl Estradiol: X (FDA)<\/li><li>Ethinyl Estradiol: B3 (AUS)<\/li><\/ul>"},{"id":"926423-s-3-12","title":"Breast Feeding","mono":"<ul><li>Drospirenone: Micromedex: Infant risk has been demonstrated.<\/li><li>Ethinyl Estradiol: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Ethinyl Estradiol: WHO: Avoid breastfeeding.<\/li><li>Ethinyl Estradiol: Micromedex: Milk effects are possible.<\/li><\/ul>"}]},"4":{"id":"926423-s-4","title":"Drug Interactions","sub":[{"id":"926423-s-4-13","title":"Contraindicated","mono":"<ul><li>Boceprevir (probable)<\/li><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"926423-s-4-14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"926423-s-4-15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"926423-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Weight change finding, Increase or decrease<\/li><li><b>Gastrointestinal:<\/b>Bloating symptom, Nausea, Stomach cramps, Vomiting<\/li><li><b>Neurologic:<\/b>Migraine<\/li><li><b>Psychiatric:<\/b>Depression<\/li><li><b>Reproductive:<\/b>Amenorrhea, Break-through bleeding, Breast tenderness, Discharge from nipple, Disorder of menstruation, Swelling of breast<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Arterial thromboembolism, Hypertension, Myocardial infarction<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder<\/li><li><b>Hematologic:<\/b>Thromboembolic disorder, Thrombophlebitis, Venous thromboembolism<\/li><li><b>Hepatic:<\/b>Neoplasm of liver<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage, Cerebral thrombosis, Thrombotic stroke<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},"6":{"id":"926423-s-6","title":"Drug Name Info","sub":{"0":{"id":"926423-s-6-17","title":"US Trade Names","mono":"<ul><li>Yasmin<\/li><li>YAZ<\/li><li>Yaz 28<\/li><li>Ocella<\/li><li>Gianvi<\/li><li>Zarah<\/li><li>Syeda<\/li><li>Loryna<\/li><\/ul>"},"2":{"id":"926423-s-6-19","title":"Class","mono":"<ul><li>Estrogen<\/li><li>Monophasic Contraceptive Combination<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"926423-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926423-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"926423-s-7","title":"Mechanism Of Action","mono":"Drospirenone\/ethinyl estradiol is an combination oral contraceptive (COC) that works primarily by suppressing ovulation. Additionally, COC agents cause cervical mucus changes that block sperm penetration and endometrial changes that reduce the chance of implantation. Although the exact mechanism of action in acne is unknown, drospirenone and ethinyl estradiol increase sex hormone binding globulin and decrease free testosterone, which may play a role.<br\/>"},"8":{"id":"926423-s-8","title":"Pharmacokinetics","sub":[{"id":"926423-s-8-23","title":"Absorption","mono":"<ul><li>Drospirenone, Tmax, Oral: 1 to 2 hours<\/li><li>Drospirenone, Bioavailability, Oral: 76%<\/li><li>Drospirenone, Effect of food: slower rate of absorption, reduced Cmax by 40%, and no effect on extent of absorption<\/li><li>Ethinyl estradiol, Tmax, Oral: 1 to 2 hours<\/li><li>Ethinyl estradiol, Bioavailability, Oral: 40%<\/li><li>Ethinyl estradiol, Effect of food: slower rate of absorption, reduced Cmax by 40%, and reduced extent of absorption by 20%<\/li><\/ul>"},{"id":"926423-s-8-24","title":"Distribution","mono":"<ul><li>Drospirenone, Vd: 4 L\/kg<\/li><li>Drospirenone, Protein binding: 97%<\/li><li>Ethinyl estradiol, Vd: 4 to 5 L\/kg<\/li><li>Ethinyl estradiol, Protein binding, Albumin: 98.5%<\/li><\/ul>"},{"id":"926423-s-8-25","title":"Metabolism","mono":"<ul><li>Drospirenone, Liver: minor extent via CYP3A4<\/li><li>Ethinyl estradiol, Liver: unknown extent via CYP3A4<\/li><li>Ethinyl estradiol, Small bowel mucosa: unknown extent<\/li><li>Ethinyl estradiol, 2-hydroxy metabolite: major<\/li><\/ul>"},{"id":"926423-s-8-26","title":"Excretion","mono":"<ul><li>Drospirenone, Fecal: trace amounts as unchanged drug; 17% to 20% excreted as glucuronide and sulfate conjugates<\/li><li>Drospirenone, Renal: trace amounts as unchanged drug; 38% to 47% excreted as glucuronide and sulfate conjugates<\/li><li>Ethinyl estradiol, Fecal: none as unchanged drug; excreted as glucuronide and sulfate conjugates<\/li><li>Ethinyl estradiol, Renal: none as unchanged drug; excreted as glucuronide and sulfate conjugates<\/li><\/ul>"},{"id":"926423-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Drospirenone: 30 hours<\/li><li>Ethinyl estradiol: 24 hours<\/li><\/ul>"}]},"9":{"id":"926423-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take exactly as directed and at intervals not exceeding 24 hours, preferably after the evening meal or at bedtime<\/li><li>nonhormonal back-up contraception should be used if the patient initiates therapy later than the first day of menstruation or if she has intercourse in the 7 days after missing 2 or more active pills in a row<\/li><li>therapy should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration<\/li><\/ul>"},"10":{"id":"926423-s-10","title":"Monitoring","mono":"<ul><li>annual history and physical; including blood pressure, cervical cytology and breast exam (in addition to monthly self-exam)<\/li><li>diagnostic measures to rule out malignancy in cases of undiagnosed, persistent\/recurrent abnormal vaginal bleeding<\/li><\/ul>"},"11":{"id":"926423-s-11","title":"How Supplied","mono":"<b>Yaz 28<\/b><br\/>Oral Tablet: (Drospirenone - Ethinyl Estradiol) 3 MG-0.02 MG<br\/>"},"13":{"id":"926423-s-13","title":"Clinical Teaching","mono":"<ul><li>Patients over 35 years of age should not smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><li>Advise patient to practice safe sex. Drug does not prevent disease transmission.<\/li><li>Discuss potential long-term adverse effects of hormone therapy including myocardial infarction, stroke, thrombophlebitis, dementia, venous thromboembolism (VTE), pulmonary embolism, and breast cancer. Inform patient that risk of VTE is greatest after initially starting therapy or restarting therapy after a 4-week or greater pill-free interval.<\/li><li>Drug may cause premenstrual syndrome, headache\/migraine, breast pain\/tenderness\/discomfort, nausea\/vomiting, fatigue, abdominal pain\/tenderness\/discomfort, weight gain, and mood changes.<\/li><li>Instruct patient to report signs\/symptoms of serious cardiovascular events, such as myocardial infarction, stroke, and arterial or venous thrombosis.<\/li><li>Patient should report new headaches that are persistent, severe, or recurrent, abnormal vaginal bleeding, amenorrhea of 2 or more consecutive cycles, or jaundice.<\/li><li>Patients should report any unexplained partial or complete loss of vision. In addition, patients who wear contact lenses should report visual changes or changes in lens tolerance.<\/li><li>This drug should be taken every day, at the same time each day, in the exact order noted on the packaging.<\/li><li>Advise patient to use a nonhormonal back-up form of contraception for the first 7 days if a Sunday-start regimen is initiated or if drug is started postpartum but before menstruation resumes.<\/li><li>Advise patient that certain drugs may cause oral contraceptives to be less effective and backup contraception may be necessary. Consult healthcare professional prior to new drug use.<\/li><li>Review with the patient the procedure for handling missed doses. It is very important that the patient follow carefully missed-dose instructions for the particular brand or formulation prescribed in order to prevent pregnancy.<\/li><\/ul>"}}}